| EMA number | EMEA/H/C/005388 |
| ATC code | H05AA02 |
| Authorisation | 27 August 2020 |
| Withdrawn | 24 November 2020 |
| Revision | - |
Qutavina is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.